United Therapeutics Corp. (UTHR) PT Raised to $447 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $587.50 +0.46%
Rating Summary:
18 Buy, 9 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
18 Buy, 9 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $447.00 (from $435.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- United Therapeutics Corp. (UTHR) PT Lowered to $697 at RBC Capital
- Third Coast Bancshares Inc (TCBX) PT Lowered to $54 at StoneX
- Pinnacle Financial Partners (PNFP) PT Raised to $115 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
